No Data
Clover Biotech-B (02197) announced its annual performance, with a loss of 0.903 billion yuan for the year.
Clover Bio-B (02197) announced its annual results for the year ending December 31, 2024, with revenues of 3841...
Express News | Clover Biopharmaceuticals FY Net Income RMB -903.4 Million
Express News | Clover Biopharmaceuticals FY Revenue RMB 11.6 Million
CLOVER BIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024
Clover Biotech-B (02197): The Global Vaccine Immunization Alliance has unilaterally terminated the pre-purchase agreement and requested the corresponding refund.
Clover Biotech-B (02197) issued an announcement regarding Clover Biopharmaceutical (Hong Kong) Limited (the company’s full...
Threeleaf Clover Biotech-B (02197.HK) announced that its RSV candidate vaccine SCB-1019 has received IND clinical trial approval from the USA and has initiated a clinical study for repeated administration.
On March 24, 2023, GSOM published an announcement that Clover Biopharmaceuticals-B (02197.HK) has received approval from the USA Food and Drug Administration (FDA) for the clinical application (IND) of its RSV candidate vaccine SCB-1019 (a bivalent RSV PreF - trimeric subunit candidate vaccine without an adjuvant, based on Clover Biopharmaceuticals Trimer-Tag protein trimerization vaccine development platform), and the Phase I clinical trial for evaluating the repeat dosing of this candidate vaccine has completed the initial enrollment of participants. The repeat dosing Phase I clinical trial being conducted in the USA has recruited up to 160 elderly subjects.
